Recent Analysts’ Ratings Updates for Nuwellis (NUWE)
by Amy Steele · The Cerbat GemA number of firms have modified their ratings and price targets on shares of Nuwellis (NASDAQ: NUWE) recently:
- 11/24/2025 – Nuwellis had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/17/2025 – Nuwellis had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/15/2025 – Nuwellis was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
- 11/11/2025 – Nuwellis had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/5/2025 – Nuwellis had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
- 10/8/2025 – Nuwellis had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
Read More
- Five stocks we like better than Nuwellis
- How to trade using analyst ratings
- Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Congress Beat the Market Again—Here Are the 3 Stocks They Bought
- 5 discounted opportunities for dividend growth investors
- Go on a Shopping Spree With 3 Top Retail ETFs